Skip to main content

Table 3 The effects of low vs high dose regimen of sildenafil on exercise capacity and echocardiographic variables

From: Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study

 

Sildenafil

Low dose effect (Baseline – 3 months)

High-dose effect (3 months – 6 months)

Overall treatment effect

PVR, Wood units

−0.56 (95% CI − 0.70 to − 0.42)**

−0.09 (95% CI − 0.20 to 0.02)

−0.65 (95% CI − 0.76 to − 0.53)**

RVOT acceleration time, ms

29 (95% CI 20 to 38)**

2 (95% CI −5 to 10)

31 (95% CI 23 to 40)**

TAPSE, cm

0.25 (95% CI 0.18 to 0.31)**

0.17 (95% CI 0.10 to 0.25)††

0.42 (95% CI 0.32 to 0.52)**

RV basal diameter, cm

−0.18 (95% CI − 0.26 to − 0.10)**

−0.12 (95% CI − 0.21 to − 0.04)††

−0.30 (95% CI − 0.42 to − 0.18)**

Mitral e′, cm/s

0.8 (95% CI 0.5 to 1.0)**

0.2 (95% CI − 0.1 to 0.5)

1.0 (95% CI 0.6 to 1.3)**

Mitral E/e′ ratio

−1.2 (95% CI − 2.0 to − 0.5)**

−1.1 (95% CI − 1.8 to − 0.4)††

− 2.4 (95% CI − 3.3 to − 1.4)**

LV mass index, g/m2

−12 (95% CI − 21 to − 4)**

−12 (95% CI − 20 to − 4)††

−24 (95% CI − 34 to − 14)**

  1. Е Early inflow velocity, e′ Annulus relaxation velocity, IVC inferior vena cava, LV left ventricular, OT outflow tract, PVR Pulmonary vascular resistance, RV Right ventricular; TAPSE Tricuspid annular plane systolic excursion
  2. * — P < 0.05, ** — P < 0.01 vs baseline
  3. † — р < 0.05, and †† — р < 0.01 vs 3 month exam